VTRS Viatris Inc. - Common Stock
$16,48
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 6, 2026
Zakres 52 tyg.
$9–$18
79% of range
Ocena Analityków
BUY
17 analysts
Cena Docelowa
$18
+12% upside
P/E (TTM)
-4.2
ROE
-23.2%
Marża Zysku Netto
-24.6%
O Viatris Inc. - Common Stock Przegląd firmy z Wikipedii
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
Czytaj więcej
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
The name of the corporation comes from the Latin words via, meaning path, and tris, which means three, referring to the path to three main objectives the corporation set: expanding access to medicines, meeting patient needs through innovation, and earning the trust of the healthcare community.
Viatris ranked 254th on the 2021 Fortune 500 rankings of the largest United States corporations based on its 2020 total revenue. In 2026, Viatris ranked 100 on Time Magazine's World's Most Impactful Companies.
History
On November 16, 2020, Upjohn merged with Mylan in a Reverse Morris Trust transaction and changed its name to Viatris. At that time, Michael Goettler became chief executive officer. Following the combination, the company began trading on the NASDAQ using the ticker symbol VTRS. In December 2020, the company announced a cost-reducing restructuring plan that would impact up to 20% of its global workforce, or 9,000 jobs at its facilities around the world.
In 2021, Viatris was ranked 5th by Fortune on its annual "Change the World" list for having "transformed the treatment of HIV around the world in the [previous] five years through the first low-cost antiretroviral drug for first-line treatment of HIV and a children's version in the form of fruit-flavored tablets that dissolve in liquid. In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. The transaction was completed in November 2022. In November 2022, the business agreed to acquire Oyster Point Pharma and Famy Life Sciences for an aggregate of $700–750 million to create an ophthalmology division. The acquisitions closed in January 2023.
In 2022 and 2024, Viatris was recognized by Forbes as one of the world's best employers and by Newsweek as one of America's most responsible companies. On April 1, 2023, Scott A. Smith became Viatris' CEO, succeeding Michael Goettler. Smith previously served on the company's board since 2022. In April 2023, Viatris was recognized by LinkedIn as one of the 25 best companies to work for in India, and one of the 25 best companies offering career development in Ireland. In May 2023, USA Today included Viatris in its list of 400 US companies that have reduced their greenhouse gas emissions intensity from 2019 to 2021. In June 2023, Viatris was named to the Forbes Global 2000 list of the world's largest companies. In October 2023, Viatris reached agreements to divest from almost all of its OTC business, its women’s healthcare business, and its India-based active pharmaceutical ingredients business for a total of about $3.6 billion.
In late December 2024, Viatris disclosed that the U.S. FDA had issued a warning letter and an import alert concerning the company's drug-making facility in Indore, India. The import alert affects 11 actively distributed products, which will no longer be accepted into the U.S. until the warning letter is lifted, while four products were conditionally exempted due to shortages. The violations cited by the FDA included subpar quality control and improper management of manufacturing defect. In response, the company announced that it has taken corrective and preventative actions.
Predecessors
The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
Products
The company produces and sells a variety of medicines, with 1,400 approved therapeutic molecules in its portfolio. It owns brands (like Viagra, Xanax, Lipitor), generics, including branded and complex generics, biosimilars, and over-the-counter (OTC) drugs and active pharmaceutical ingredients. Viatris products cover therapeutic areas including cardiovascular, infectious disease, oncology, immunology, CNS and anesthesia, women's healthcare, diabetes and metabolism, gastroenterology, respiratory and allergy, and dermatology.
The following products have been newly launched or received regulatory approvals since Viatris was established include:
Dolutegravir: In December 2020, received FDA approval to treat children with HIV/AIDS in low to middle income countries. The formulation is strawberry-flavored to make it easier to give to children and was made available at a 75% discount compared to previous treatments.
Breyna (budesonide and formoterol fumarate dihydrate inhalation aerosol): In March 2022, received approval from the US FDA in March 2022 as the first generic version of Symbicort for the treatment of asthma and COPD.
GA Depot (long-acting version of glatiramer acetate): In August 2023, received New Drug Application acceptance from the US FDA as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis.
Abacavir/dolutegravir/lamivudine: In September 2023, received tentative US FDA approval for a New Drug Application through the President's Emergency Plan for AIDS Relief (PEPFAR) for the treatment of HIV-1 infection in pediatric patients.
Ryzumvi (phentolamine ophthalmic solution 0.75%): In September 2023, received FDA approval for the treatment of mydriasis caused by adrenergic agonist or parasympatholytic agents or a combination of those drugs. It was previously known as Nyxol.
Partnerships
Following the formation of Viatris, the company became a member of the Biosimilars Forum, a trade organization that advocates for greater biosimilar usage. Viatris partnered with the American College of Cardiology, the NCD Alliance, and the World Heart Federation to create the NCD Academy, a platform to help fight non-communicable diseases around the world.
In December 2020, the company worked with Sesame Workshop to create resources to help children and their caregivers manage their social and emotional needs impacted by the COVID-19 pandemic. In April 2021, the company partnered with Atomo Diagnostics and Unitaid to expand access to HIV self-testing to 135 countries and lower the price of the tests by around 50%.
In February 2024, Viatris entered into an agreement with Idorsia to collaborate on global research and development and the commercialization rights to Phase 3 pharmaceuticals selatogrel, a cardiac medication, and cenerimod, a novel immunology medication used to treat systemic lupus erythematosus. The agreement includes the potential to add more assets in the future.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
VTRS Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$16.48
Kapitalizacja Rynkowa
—
P/E (TTM)
-4.2
EPS (TTM)
$-3.00
Przychody (TTM)
$14.30B
Stopa dywidendy
—
ROE
-23.2%
D/E Dług/Kapitał
1.0
Zakres 52 tyg.
$9 – $18
VTRS Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$14.30B
2018-12-31
→
2025-12-31
EPS
$-3.00
2018-12-31
→
2025-12-31
Wolny przepływ pieniężny
$1.94B
2025-12-31
→
2025-12-31
Marże
-24.6%
2025-12-31
→
2025-12-31
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
VTRS
Mediana porównawcza
P/E (TTM)
-4.2
32.1
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
VTRS
Mediana porównawcza
Gross Margin (Marża brutto)
35.1%
71.8%
Operating Margin (Marża Operacyjna)
-18.6%
—
Net Profit Margin (Marża Zysku Netto)
-24.6%
13.0%
ROA
-8.9%
6.4%
ROE
-23.2%
15.1%
ROIC
-8.8%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
VTRS
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
1.0
—
Current Ratio (Wskaźnik bieżący)
1.4
1.6
Quick Ratio (Wskaźnik Szybkości)
0.6
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
VTRS
Mediana porównawcza
Revenue YoY (Przychody R/R)
-3.0%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
-4.2%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
3.7%
—
EPS YoY
-97.1%
—
Net Income YoY (Zysk Netto R/R)
-97.4%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
VTRS
Mediana porównawcza
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
Stopa Dywidendy
—
Wskaźnik Wypłaty Dywidendy
—
CAGR dywidendy 5-letni
—
| Data ex-dywidendy | Kwota |
|---|---|
| 22 maja 2026 | $0,1200 |
| 9 marca 2026 | $0,1200 |
| 24 listopada 2025 | $0,1200 |
| 22 sierpnia 2025 | $0,1200 |
| 23 maja 2025 | $0,1200 |
| 10 marca 2025 | $0,1200 |
| 22 listopada 2024 | $0,1200 |
| 23 sierpnia 2024 | $0,1200 |
| 23 maja 2024 | $0,1200 |
| 8 marca 2024 | $0,1200 |
| 22 listopada 2023 | $0,1200 |
| 23 sierpnia 2023 | $0,1200 |
| 23 maja 2023 | $0,1200 |
| 8 marca 2023 | $0,1200 |
| 22 listopada 2022 | $0,1200 |
| 23 sierpnia 2022 | $0,1200 |
| 23 maja 2022 | $0,1200 |
| 23 lutego 2022 | $0,1200 |
| 22 listopada 2021 | $0,1100 |
| 23 sierpnia 2021 | $0,1100 |
VTRS Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
17 analityków
- Mocne kupno 4 23,5%
- Kup 7 41,2%
- Trzymaj 5 29,4%
- Sprzedaj 1 5,9%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
8 analityków · 2026-08-19
Mediana
$19.00
Teraz
$16.48
Niski
$12.00
Wysoki
$23.00
Średni cel
$19.00
+15,3%
Średnia cel
$18.50
+12,3%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.05%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $0.69 | $0.61 | 0.08% |
| 31 marca 2026 | $0.59 | $0.51 | 0.08% |
| 31 grudnia 2025 | $0.57 | $0.54 | 0.03% |
| 30 września 2025 | $0.67 | $0.63 | 0.04% |
| 30 czerwca 2025 | $0.62 | $0.57 | 0.05% |
| 31 marca 2025 | $0.50 | $0.50 | 0.00% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| VTRS | — | -4.2 | -3.0% | -24.6% | -23.2% | 35.1% |
| MRK | — | 14.5 | 1.3% | 28.1% | 36.9% | — |
| PFE | — | 18.3 | -1.7% | 12.4% | 8.9% | — |
| BMY | — | 15.6 | -0.22% | 14.6% | 40.5% | — |
| RPRX | — | 21.7 | 5.1% | 32.4% | 8.0% | — |
| ZTS | $53.46B | 20.9 | 2.3% | 28.2% | 66.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 17
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | $11.43B | |
| Cost of Revenue | $9.29B | $9.12B | $8.99B | $9.77B | $12.31B | $8.15B | $7.60B | $7.43B | |
| Gross Profit | $5.01B | $5.62B | $6.44B | $6.50B | $5.58B | $3.80B | $3.90B | $4.00B | |
| R&D Expense | · | · | · | · | $751M | $555M | $640M | $704M | |
| SG&A Expense | $3.79B | $4.10B | $4.07B | $4.18B | $4.53B | $3.34B | $2.56B | $2.44B | |
| Operating Expenses | $7.68B | $5.61B | $5.67B | $4.88B | $5.61B | $4.01B | $3.18B | $3.10B | |
| Operating Income | $-2.66B | $10M | $766M | $1.61B | $-34M | $-211M | $716M | $906M | |
| Interest Expense | $471M | $550M | $573M | $592M | $636M | $498M | $517M | $542M | |
| Other Non-op | $-531M | $-83M | $10M | $1.79B | $6M | $-13M | $-44M | $-65M | |
| Pretax Income | $-3.67B | $-623M | $203M | $2.81B | $-664M | $-721M | $154M | $298M | |
| Income Tax | $-150M | $11M | $148M | $735M | $605M | $-51M | $138M | $-54M | |
| Net Income | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | $352M | |
| EPS (Basic) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.69 | |
| EPS (Diluted) | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 | $-1.11 | $0.03 | $0.68 | |
| Shares (Basic) | · | · | 1,200,300,000 | 1,212,100,000 | 1,208,800,000 | 601,200,000 | 515,700,000 | 514,500,000 | |
| Shares (Diluted) | · | · | 1,206,900,000 | 1,217,400,000 | 1,208,800,000 | 601,200,000 | 516,500,000 | 516,500,000 | |
| EBITDA | $135M | · | · | · | · | · | · | · |
Bilans 30
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.32B | $735M | $992M | $1.26B | $701M | $844M | $476M | $388M | |
| Short-term Investments | · | · | · | · | · | $39M | $27M | · | |
| Receivables | $3.03B | $3.22B | $3.70B | $3.81B | $4.27B | $4.84B | $3.06B | · | |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | $3.98B | $5.47B | $2.67B | · | |
| Prepaid Expense | $1.44B | $1.71B | $2.03B | $1.81B | $1.96B | $1.71B | $552M | · | |
| Other Current Assets | $136M | $387M | $271M | $328M | $1.47B | $1.24B | $286M | · | |
| Current Assets | $9.79B | $9.52B | $12.98B | $10.64B | $10.90B | $12.87B | $6.76B | · | |
| PP&E (Net) | $2.61B | $2.67B | $2.76B | $3.02B | $3.19B | $3.46B | $2.15B | · | |
| PP&E (Gross) | $5.13B | $4.87B | $4.77B | $5.08B | $5.59B | $5.72B | $4.12B | · | |
| Accum. Depreciation | $2.52B | $2.20B | $2.01B | $2.06B | $2.40B | $2.26B | $1.97B | · | |
| Goodwill | $6.75B | $9.13B | $9.87B | $10.43B | $12.11B | $12.35B | $9.59B | $9.75B | |
| Intangibles | $15.10B | $17.07B | $19.18B | $22.61B | $26.13B | $29.68B | $11.65B | · | |
| Other Non-current Assets | $1.87B | $2.36B | $2.21B | $2.40B | $1.17B | $1.05B | $405M | · | |
| Total Assets | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Short-term Debt | · | · | · | $0 | $1.49B | $1.10B | $0 | · | |
| Current Liabilities | $7.09B | $5.78B | $7.78B | $6.75B | $9.88B | $10.56B | $5.57B | · | |
| Capital Leases | $178M | $179M | $165M | $181M | $201M | $230M | $176M | · | |
| Deferred Tax | $892M | $1.11B | $1.74B | $2.43B | $2.81B | $3.12B | $1.63B | · | |
| Other Non-current Liabilities | $2.01B | $1.94B | $1.52B | $1.76B | $1.93B | $2.48B | $961M | · | |
| Total Liabilities | $22.48B | $22.87B | $27.22B | $28.95B | $34.35B | $38.60B | $19.37B | · | |
| Long-term Debt | $14.41B | $14.05B | $18.13B | $19.27B | $21.59B | $24.74B | $12.72B | · | |
| Total Debt | $14.41B | · | · | · | · | · | · | · | |
| Common Stock | $12M | $12M | $12M | $12M | $12M | $12M | $6M | · | |
| Paid-in Capital | $18.80B | $18.92B | $18.81B | $18.65B | $18.54B | $18.44B | $8.64B | · | |
| Retained Earnings | $-388M | $3.42B | $4.64B | $5.18B | $3.69B | $5.36B | $6.03B | · | |
| Treasury Stock | $1.01B | $504M | $252M | $0 | $0 | $0 | $1000M | · | |
| AOCI | $-2.71B | $-3.21B | $-2.75B | $-2.76B | $-1.74B | $-858M | $-1.80B | · | |
| Stockholders' Equity | $14.71B | $18.64B | $20.47B | $21.07B | $20.49B | $22.95B | $11.88B | $12.17B | |
| Liabilities + Equity | $37.19B | $41.50B | $47.69B | $50.02B | $54.84B | $61.55B | $31.26B | · | |
| Shares Outstanding | · | · | · | · | · | · | 100 | · |
Przepływy pieniężne 19
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.80B | $2.89B | $2.74B | $3.03B | $4.51B | $2.22B | $2.02B | $2.11B | |
| Stock-based Comp | $178M | $146M | $181M | $116M | $111M | $79M | $57M | $-3M | |
| Deferred Tax | $-476M | $-768M | $-387M | $-26M | $676M | $-213M | $-193M | $-264M | |
| Amort. of Intangibles | $2.35B | $2.35B | $2.32B | $2.50B | $2.70B | $1.61B | $1.58B | $1.61B | |
| Restructuring | · | · | · | · | $50M | $50M | $105M | · | |
| Other Non-cash | $3.33B | · | · | · | · | · | · | · | |
| Operating Cash Flow | $2.32B | $2.30B | $2.90B | $3.00B | $3.02B | $1.23B | $1.80B | $2.34B | |
| CapEx | $379M | $326M | $377M | $406M | $457M | $243M | $213M | $252M | |
| Investing Cash Flow | $-428M | $1.80B | $-864M | $1.47B | $-118M | $-301M | $-525M | $-1.21B | |
| Debt Issued | $0 | $0 | $300.0K | $1.88B | $1.71B | $983M | $7M | $2.58B | |
| Net Debt Issued | $-100.0K | · | · | · | · | · | · | · | |
| Stock Issued | $3M | $2M | $3M | $3M | $0 | $0 | · | · | |
| Stock Repurchased | $500M | $250M | $250M | $0 | $0 | $0 | $0 | $432M | |
| Net Stock Activity | $-498M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-1.29B | $-4.33B | $-2.30B | $-3.88B | $-3.01B | $-606M | $-1.17B | $-1.09B | |
| Net Change in Cash | $612M | $-258M | $-269M | $556M | $-144M | $359M | $102M | $19M | |
| Taxes Paid | $445M | · | · | · | · | · | · | · | |
| Free Cash Flow | $1.94B | · | · | · | · | · | · | · | |
| Levered FCF | $1.49B | · | · | · | · | · | · | · |
Rentowność 8
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 35.1% | · | · | · | · | · | · | · | |
| Operating Margin | -18.6% | · | · | · | · | · | · | · | |
| Net Margin | -24.6% | · | · | · | · | · | · | · | |
| Pretax Margin | -25.6% | · | · | · | · | · | · | · | |
| EBITDA Margin | 0.95% | · | · | · | · | · | · | · | |
| ROA | -8.9% | · | · | · | · | · | · | · | |
| ROE | -23.2% | · | · | · | · | · | · | · | |
| ROIC | -8.8% | · | · | · | · | · | · | · |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.4 | · | · | · | · | · | · | · | |
| Quick Ratio | 0.6 | · | · | · | · | · | · | · | |
| Debt / Equity | 1.0 | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.8 | · | · | · | · | · | · | · | |
| Interest Coverage | -5.7 | · | · | · | · | · | · | · |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | · | · | · | · | · | · | · | |
| Inventory Turnover | 2.4 | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.6 | · | · | · | · | · | · | · |
Stopy Wzrostu 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -3.0% | -4.5% | -5.1% | -9.1% | 49.7% | · | · | · | |
| Revenue CAGR 3Y | -4.2% | -6.2% | 8.9% | · | · | · | · | · | |
| Revenue CAGR 5Y | 3.7% | · | · | · | · | · | · | · | |
| EPS YoY | · | · | -97.1% | · | · | · | · | · | |
| Net Income YoY | · | · | -97.4% | · | · | · | · | · |
Wycena (TTM) 6
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B | $11.95B | $11.50B | · | |
| Net Income TTM | $-3.51B | $-634M | $55M | $2.08B | $-1.27B | $-670M | $17M | · | |
| Market Cap | · | · | · | · | · | · | $2.0K | · | |
| P/E | -4.2 | -23.5 | 216.6 | 6.5 | -12.9 | -16.9 | 670.0 | · | |
| P/S | · | · | · | · | · | · | 0.0 | · | |
| Earnings Yield | -24.1% | -4.3% | 0.46% | 15.4% | -7.8% | -5.9% | 0.15% | · |
Rachunek zysków i strat 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.76B | $3.52B | $3.70B | $3.76B | $3.58B | $3.25B | $3.53B | $3.75B | $3.80B | $3.66B | $3.84B | $3.94B | $3.92B | $3.73B | $3.88B | $4.08B | |
| Cost of Revenue | $2.30B | $2.36B | $2.56B | $2.39B | $2.25B | $2.09B | $2.31B | $2.29B | $2.35B | $2.16B | $2.24B | $2.25B | $2.31B | $2.19B | $2.60B | $2.33B | |
| Gross Profit | $1.46B | $1.16B | $1.15B | $1.37B | $1.33B | $1.16B | $1.22B | $1.46B | $1.45B | $1.50B | $1.60B | $1.69B | $1.61B | $1.54B | $1.27B | $1.75B | |
| R&D Expense | $248M | $249M | · | $250M | $219M | $222M | · | $198M | $204M | $200M | · | $211M | $208M | $183M | · | $175M | |
| SG&A Expense | $1.13B | $929M | $1.03B | $887M | $929M | $948M | $1.05B | $1.00B | $1.04B | $1.02B | $1.03B | $1.05B | $1.03B | $959M | $1.27B | $1.02B | |
| Operating Expenses | $1.45B | $1.24B | $1.34B | $1.19B | $1.10B | $4.04B | $1.39B | $1.23B | $1.69B | $1.30B | $2.05B | $1.24B | $1.24B | $1.14B | $1.48B | $1.19B | |
| Operating Income | $6M | $-80M | $-193M | $179M | $233M | $-2.88B | $-180M | $226M | $-240M | $204M | $-454M | $452M | $369M | $400M | $-201M | $560M | |
| Interest Expense | $121M | $120M | $120M | $120M | $117M | $116M | $120M | $146M | $146M | $138M | $141M | $142M | $144M | $147M | $147M | $153M | |
| Other Non-op | $50M | $-48M | $-31M | $-67M | $-334M | $-99M | $-226M | $10M | $-6M | $139M | $-260M | $92M | $108M | $70M | $1.82B | $21M | |
| Pretax Income | $-64M | $-247M | $-343M | $-8M | $-217M | $-3.10B | $-526M | $90M | $-392M | $205M | $-855M | $402M | $333M | $323M | $1.47B | $428M | |
| Income Tax | $55M | $-424M | $-3M | $120M | $-212M | $-55M | $-10M | $-4M | $-65M | $91M | $-89M | $71M | $69M | $98M | $458M | $73M | |
| EPS (Basic) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.44 | $0.08 | $-0.27 | $0.10 | $-0.64 | $0.28 | $0.22 | $0.19 | $0.83 | $0.29 | |
| EPS (Diluted) | $-0.10 | $0.15 | $-0.34 | $-0.11 | $0.00 | $-2.55 | $-0.43 | $0.08 | $-0.27 | $0.09 | $-0.63 | $0.27 | $0.22 | $0.19 | $0.83 | $0.29 | |
| Shares (Basic) | 1,163,300,000 | 1,155,400,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,193,500,000 | 1,191,100,000 | 1,195,200,000 | -2,400,700,000 | 1,199,500,000 | 1,199,000,000 | 1,202,500,000 | -2,423,200,000 | 1,212,500,000 | |
| Shares (Diluted) | 1,163,300,000 | 1,175,300,000 | · | 1,164,600,000 | 1,173,000,000 | 1,192,400,000 | · | 1,200,400,000 | 1,191,100,000 | 1,209,500,000 | -2,409,800,000 | 1,207,600,000 | 1,203,500,000 | 1,205,600,000 | -2,430,900,000 | 1,218,100,000 | |
| EBITDA | $6M | $596M | · | $179M | $233M | $-2.22B | · | $226M | $-240M | $895M | · | $452M | $369M | $1.13B | · | $560M |
Bilans 28
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $886M | $1.80B | $1.32B | $975M | $566M | $755M | $735M | $1.88B | $917M | $1.01B | $992M | $1.31B | $629M | $507M | $1.26B | $647M | |
| Receivables | $3.13B | $3.08B | $3.03B | $3.37B | $3.26B | $3.13B | $3.22B | $3.72B | $3.57B | $3.63B | · | $3.74B | $3.61B | $3.50B | · | $3.33B | |
| Inventory | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | $4.10B | $3.85B | $4.08B | $3.94B | $3.82B | · | $3.67B | $3.64B | $3.66B | · | $3.38B | |
| Prepaid Expense | $2.11B | $2.11B | $1.44B | $1.49B | $1.69B | $1.65B | $1.71B | $1.63B | $1.76B | $1.93B | · | $1.78B | $1.73B | $1.76B | · | $1.70B | |
| Other Current Assets | $140M | $98M | $136M | $251M | $259M | $355M | $387M | $335M | $270M | $250M | · | $1.20B | $1.18B | $1.35B | · | $1.13B | |
| Current Assets | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | $9.62B | $9.52B | $11.31B | $11.79B | $12.92B | · | $10.93B | $9.78B | $9.63B | · | $10.49B | |
| PP&E (Net) | $2.44B | $2.53B | $2.61B | $2.63B | $2.64B | $2.64B | $2.67B | $2.68B | $2.66B | $2.71B | · | $2.93B | $2.98B | $3.01B | · | $3.04B | |
| PP&E (Gross) | $5.11B | $5.11B | $5.13B | $5.11B | $5.07B | $4.94B | $4.87B | $4.88B | $4.71B | $4.71B | · | $5.04B | $5.05B | $5.15B | · | $5.02B | |
| Accum. Depreciation | $2.67B | $2.58B | $2.52B | $2.48B | $2.42B | $2.30B | $2.20B | $2.21B | $2.05B | $2.00B | · | $2.11B | $2.06B | $2.14B | · | $1.98B | |
| Goodwill | $6.65B | $6.69B | $6.75B | $6.73B | $6.75B | $6.46B | $9.13B | $9.56B | $9.33B | $9.69B | $9.87B | $10.28B | $10.53B | $10.57B | $10.43B | $10.05B | |
| Intangibles | $13.68B | $14.48B | $15.10B | $15.72B | $16.32B | $16.66B | $17.07B | $17.98B | $18.42B | $19.13B | · | $21.28B | $22.08B | $22.70B | · | $23.01B | |
| Other Non-current Assets | $1.06B | $1.11B | $1.87B | $1.89B | $2.00B | $2.27B | $2.36B | $2.47B | $2.45B | $2.23B | · | $2.40B | $2.35B | $2.42B | · | $964M | |
| Total Assets | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B | |
| Short-term Debt | · | · | · | · | · | · | · | · | · | · | · | $100.0K | $23M | $205M | · | $500M | |
| Current Liabilities | $6.35B | $6.81B | $7.09B | $7.36B | $7.13B | $5.72B | $5.78B | $7.51B | $7.71B | $7.76B | · | $6.83B | $6.52B | $6.11B | · | $6.52B | |
| Capital Leases | $160M | $167M | $178M | $171M | $182M | $177M | $179M | $188M | $192M | $156M | · | $160M | $167M | $173M | · | $179M | |
| Deferred Tax | $803M | $871M | $892M | $1.03B | $1.08B | $1.08B | $1.11B | $1.28B | $1.57B | $1.67B | · | $2.32B | $2.41B | $2.46B | · | $2.49B | |
| Other Non-current Liabilities | $2.02B | $2.08B | $2.01B | $1.82B | $1.84B | $1.84B | $1.94B | $1.87B | $1.80B | $1.83B | · | $1.65B | $1.67B | $1.72B | · | $1.75B | |
| Total Liabilities | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | $22.82B | $22.87B | $24.96B | $25.81B | $27.33B | · | $27.88B | $27.85B | $28.36B | · | $29.48B | |
| Long-term Debt | $13.35B | $14.34B | $14.41B | $14.44B | $14.47B | $14.19B | $14.05B | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.58B | $18.58B | · | $19.49B | |
| Total Debt | $13.35B | $14.34B | · | $14.44B | $14.47B | $14.19B | · | $15.75B | $17.10B | $17.97B | · | $18.38B | $18.60B | $18.78B | · | $19.99B | |
| Common Stock | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | $12M | · | $12M | $12M | $12M | · | $12M | |
| Paid-in Capital | $18.56B | $18.66B | $18.80B | $18.89B | $19.00B | $18.96B | $18.92B | $18.89B | $18.85B | $18.84B | · | $18.76B | $18.72B | $18.68B | · | $18.62B | |
| Retained Earnings | $-331M | $-212M | $-388M | $-48M | $80M | $228M | $3.42B | $4.08B | $4.13B | $4.61B | · | $5.55B | $5.37B | $5.25B | · | $4.31B | |
| Treasury Stock | $1.16B | $1.01B | $1.01B | $924M | $856M | $680M | $504M | $504M | $504M | $504M | · | $252M | $252M | $252M | · | · | |
| AOCI | $-2.82B | $-2.80B | $-2.71B | $-2.71B | $-2.66B | $-2.87B | · | $-2.69B | $-2.98B | $-2.94B | · | $-3.21B | $-3.01B | $-2.76B | · | $-3.76B | |
| Stockholders' Equity | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | $15.65B | $18.64B | $19.79B | $19.52B | $20.01B | $20.47B | $20.87B | $20.84B | $20.93B | $21.07B | $19.18B | |
| Liabilities + Equity | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | $38.47B | $41.50B | $44.75B | $45.33B | $47.34B | · | $48.74B | $48.70B | $49.29B | · | $48.66B |
Przepływy pieniężne 17
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $672M | $676M | $767M | $688M | $678M | $665M | $746M | $670M | $786M | $691M | $644M | $679M | $687M | $730M | $870M | $700M | |
| Stock-based Comp | $39M | $48M | $49M | $36M | $37M | $55M | $32M | $32M | $35M | $47M | $56M | $43M | $39M | $43M | $30M | $29M | |
| Deferred Tax | $-124M | $-70M | $-248M | $-137M | $-48M | $-44M | $-249M | $-312M | $-154M | $-52M | $-207M | $-85M | $-68M | $-27M | $154M | $-22M | |
| Amort. of Intangibles | $572M | $585M | $602M | $593M | $583M | $571M | $579M | $575M | $597M | $601M | $539M | $584M | $591M | $603M | $606M | $616M | |
| Restructuring | $27M | $78M | · | · | · | · | · | · | · | · | · | $15M | $74M | $10M | · | $15M | |
| Operating Cash Flow | $382M | $388M | $816M | $745M | $220M | $536M | $483M | $826M | $379M | $615M | $568M | $845M | $525M | $971M | $189M | $869M | |
| CapEx | $53M | $40M | $196M | $87M | $53M | $43M | $140M | $77M | $59M | $50M | $166M | $96M | $68M | $48M | $154M | $104M | |
| Investing Cash Flow | $-52M | $277M | $-211M | $-99M | $-52M | $-65M | $-169M | $1.75B | $376M | $-154M | $27M | $-65M | $-87M | $-750M | $1.74B | $-115M | |
| Debt Issued | · | · | · | · | · | · | · | · | · | · | $300.0K | $0 | $0 | $0 | $100.0K | $1.08B | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $-750M | · | · | |
| Stock Issued | $700.0K | $500.0K | $600.0K | $700.0K | $700.0K | $600.0K | $600.0K | $600.0K | $700.0K | $600.0K | $600.0K | $800.0K | $800.0K | $900.0K | $800.0K | $2M | |
| Stock Repurchased | $150M | $0 | $82M | $68M | $175M | $175M | $0 | $0 | $0 | $250M | $0 | $0 | $0 | $250M | $0 | $0 | |
| Net Stock Activity | · | $500.0K | · | $-68M | $-175M | $-175M | · | · | · | $-249M | · | · | · | $-249M | · | · | |
| Financing Cash Flow | $-1.24B | $-204M | $-236M | $-228M | $-362M | $-467M | $-1.42B | $-1.64B | $-848M | $-426M | $-926M | $-98M | $-304M | $-975M | $-1.33B | $-759M | |
| Net Change in Cash | $-916M | $458M | $344M | $436M | $-188M | $20M | $-1.14B | $962M | $-97M | $22M | $-318M | $680M | $121M | $-752M | $612M | $-19M | |
| Free Cash Flow | · | $348M | · | · | · | $493M | · | · | · | $565M | · | · | · | $923M | · | · | |
| Levered FCF | · | $434M | · | · | · | $379M | · | · | · | $488M | · | · | · | $821M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 38.8% | 32.9% | · | 36.5% | 37.2% | 35.7% | · | 38.9% | 38.1% | 41.0% | · | 42.9% | 41.0% | 41.4% | · | 42.9% | |
| Operating Margin | 0.17% | -2.3% | · | 4.8% | 6.5% | -88.6% | · | 6.0% | -6.3% | 5.6% | · | 11.5% | 9.4% | 10.7% | · | 13.7% | |
| Pretax Margin | -1.7% | -7.0% | · | -0.21% | -6.1% | -95.2% | · | 2.4% | -10.3% | 5.6% | · | 10.2% | 8.5% | 8.6% | · | 10.5% | |
| EBITDA Margin | 0.17% | 17.0% | · | 4.8% | 6.5% | -68.1% | · | 6.0% | -6.3% | 24.4% | · | 11.5% | 9.4% | 30.3% | · | 13.7% | |
| ROIC | 0.04% | 0.20% | · | 9.8% | 0.02% | -9.5% | · | 0.67% | -0.55% | 0.30% | · | 0.95% | 0.74% | 0.70% | · | 1.2% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 1.6 | · | 1.4 | 1.4 | 1.7 | · | 1.5 | 1.5 | 1.7 | · | 1.6 | 1.5 | 1.6 | · | 1.6 | |
| Quick Ratio | 0.6 | 0.7 | · | 0.6 | 0.5 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.7 | 0.6 | 0.7 | · | 0.6 | |
| Debt / Equity | 0.9 | 1.0 | · | 0.9 | 0.9 | 0.9 | · | 0.8 | 0.9 | 0.9 | · | 0.9 | 0.9 | 0.9 | · | 1.0 | |
| LT Debt / Equity | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 0.7 | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Interest Coverage | 0.1 | -0.7 | · | 1.5 | 2.0 | -25.0 | · | 1.6 | -1.6 | 1.5 | · | 3.2 | 2.6 | 2.7 | · | 3.7 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.6 | 0.6 | · | 0.6 | 0.5 | 0.5 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | 0.6 | |
| Receivables Turnover | 1.2 | 1.1 | · | 1.1 | 1.0 | 1.0 | · | 1.0 | 1.1 | 1.0 | · | 1.1 | 1.1 | 1.0 | · | 1.1 |
Wycena (TTM) 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14.62B | $14.11B | · | $14.35B | $14.38B | $14.47B | · | $15.15B | $15.32B | $15.25B | · | $15.67B | $15.84B | $16.12B | · | $16.92B | |
| Net Income TTM | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | $-170M | $-170M | · | $-170M | |
| P/E | -264.7 | -5.4 | · | -3.8 | -3.3 | -3.3 | · | 68.3 | 34.3 | 15.5 | · | 10.2 | 10.4 | 9.0 | · | 7.5 | |
| Earnings Yield | -0.38% | -18.6% | · | -26.1% | -30.7% | -30.4% | · | 1.5% | 2.9% | 6.5% | · | 9.8% | 9.6% | 11.1% | · | 13.4% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Przychody | $14.30B | $14.74B | $15.43B | $16.26B | $17.89B |
| Marża Brutto % | 35.1% | — | — | — | — |
| Marża Operacyjna % | -18.6% | — | — | — | — |
| Zysk netto | $-3.51B | $-634M | $55M | $2.08B | $-1.27B |
| Rozwodniony EPS | $-3.00 | $-0.53 | $0.05 | $1.71 | $-1.05 |
Bilans
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 1.0 | — | — | — | — |
| Wskaźnik bieżący | 1.4 | — | — | — | — |
| Wskaźnik Szybkości | 0.6 | — | — | — | — |
Przepływy pieniężne
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $1.94B | — | — | — | — |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 1 132 emitenci · $12.6B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 113 (-35 vs poprzedni kw.) | 87 (0 vs poprzedni kw.) | 352 (+15 vs poprzedni kw.) | 311 (+5 vs poprzedni kw.) | +245.4M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1 590 154 649 | 127 723 265 | 12,66% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $1 207 625 391 | 76 046 939 | 9,61% | Akcje |
| Davis Selected Advisers | $1 194 789 797 | 75 232 254 | 9,51% | Akcje |
| FMR LLC | $992 936 353 | 62 527 478 | 7,91% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $861 999 430 | 54 282 080 | 6,86% | Akcje |
| STATE STREET CORP | $842 743 041 | 53 069 461 | 6,71% | Akcje |
| Rubric Capital Management LP | $542 599 639 | 34 168 743 | 4,32% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $458 542 313 | 28 931 625 | 3,65% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $425 986 168 | 26 825 324 | 3,39% | Akcje |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $320 873 980 | 20 206 170 | 2,55% | Akcje |
| AMERIPRISE FINANCIAL INC | $294 863 935 | 18 568 141 | 2,35% | Akcje |
| GLENVIEW CAPITAL MANAGEMENT, LLC | $156 853 255 | 9 877 409 | 1,25% | Akcje |
| GOLDMAN SACHS GROUP INC | $138 959 750 | 8 750 614 | 1,11% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $132 934 942 | 8 371 218 | 1,06% | Akcje |
| Callodine Capital Management, LP | $127 051 783 | 8 000 742 | 1,01% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $103 910 383 | 6 543 475 | 0,83% | Akcje |
| Qube Research & Technologies Ltd | $98 141 941 | 6 180 223 | 0,78% | Akcje |
| Nantahala Capital Management, LLC | $79 400 000 | 5 000 000 | 0,63% | Opcja kupna |
| Assenagon Asset Management S.A. | $79 225 415 | 4 989 006 | 0,63% | Akcje |
| AMERICAN CENTURY COMPANIES INC | $73 760 258 | 4 644 851 | 0,59% | Akcje |
| FRANKLIN RESOURCES INC | $73 433 026 | 4 624 246 | 0,58% | Akcje |
| Gotham Asset Management, LLC | $69 469 966 | 4 374 683 | 0,55% | Akcje |
| Brandywine Global Investment Management, LLC | $67 528 501 | 5 423 976 | 0,54% | Akcje |
| NORGES BANK | $60 705 175 | 3 822 744 | 0,48% | Akcje |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $59 326 092 | 3 735 900 | 0,47% | Akcje |
| BlackRock, Inc. | $50 770 853 | 3 197 157 | 0,40% | Akcje |
| RHUMBLINE ADVISERS | $45 614 656 | 2 872 464 | 0,36% | Akcje |
| Vanguard Global Advisers, LLC | $42 862 486 | 2 699 149 | 0,34% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $42 610 407 | 2 683 275 | 0,34% | Akcje |
| FLPUTNAM INVESTMENT MANAGEMENT CO | $42 249 391 | 2 660 541 | 0,34% | Akcje |
| California Public Employees Retirement System | $40 629 123 | 2 558 509 | 0,32% | Akcje |
| ARGENT CAPITAL MANAGEMENT LLC | $40 499 641 | 2 550 355 | 0,32% | Akcje |
| DME Capital Management, LP | $39 761 614 | 2 503 880 | 0,32% | Akcje |
| Pictet Asset Management Holding SA | $39 481 647 | 2 437 987 | 0,31% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $37 396 986 | 2 354 974 | 0,30% | Akcje |
| Swiss National Bank | $37 102 064 | 2 336 402 | 0,30% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $34 474 638 | 2 170 947 | 0,27% | Akcje |
| FIL Ltd | $33 643 336 | 2 118 598 | 0,27% | Akcje |
| Robeco Institutional Asset Management B.V. | $33 037 834 | 2 080 468 | 0,26% | Akcje |
| BARCLAYS PLC | $32 535 722 | 2 048 849 | 0,26% | Akcje |
| Allianz Asset Management GmbH | $32 188 236 | 2 026 967 | 0,26% | Akcje |
| Legal & General Group Plc | $31 446 226 | 1 980 241 | 0,25% | Akcje |
| BANK OF NOVA SCOTIA | $28 130 467 | 1 771 440 | 0,22% | Akcje |
| SEI INVESTMENTS CO | $28 129 290 | 1 771 366 | 0,22% | Akcje |
| BANK OF AMERICA CORP /DE/ | $28 053 767 | 1 766 610 | 0,22% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $27 953 373 | 1 760 288 | 0,22% | Akcje |
| TORONTO DOMINION BANK | $27 612 303 | 1 738 810 | 0,22% | Akcje |
| Invenomic Capital Management LP | $27 611 985 | 1 738 790 | 0,22% | Akcje |
| Bridgewater Associates, LP | $26 969 655 | 1 698 341 | 0,21% | Akcje |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $26 265 777 | 1 944 173 | 0,21% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $24 676 772 | 1 553 953 | 0,20% | Akcje |
| Camber Capital Management LP | $24 557 500 | 2 750 000 | 0,20% | Akcje |
| Arnhold LLC | $23 200 267 | 1 460 974 | 0,18% | Akcje |
| MANNING & NAPIER ADVISORS LLC | $23 136 612 | 1 425 546 | 0,18% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $22 918 445 | 1 443 227 | 0,18% | Akcje |
| MOORE CAPITAL MANAGEMENT, LP | $22 718 786 | 1 430 654 | 0,18% | Akcje |
| Quantinno Capital Management LP | $21 730 727 | 1 368 433 | 0,17% | Akcje |
| Quaker Capital Investments, LLC | $21 567 486 | 1 358 154 | 0,17% | Akcje |
| MOORE CAPITAL MANAGEMENT, LP | $21 126 752 | 1 330 400 | 0,17% | Opcja sprzedaży |
| STATE OF WISCONSIN INVESTMENT BOARD | $20 950 929 | 1 319 328 | 0,17% | Akcje |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $20 773 000 | 1 308 106 | 0,17% | Akcje |
| Man Group plc | $20 719 636 | 1 304 763 | 0,16% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $19 978 215 | 1 258 074 | 0,16% | Akcje |
| Caption Management, LLC | $19 850 000 | 1 250 000 | 0,16% | Opcja sprzedaży |
| Monaco Asset Management SAM | $19 287 419 | 1 214 573 | 0,15% | Akcje |
| UBS Group AG | $18 638 340 | 1 173 699 | 0,15% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $18 213 709 | 1 348 165 | 0,15% | Akcje |
| ARCADIA INVESTMENT MANAGEMENT CORP/MI | $17 959 195 | 1 329 326 | 0,14% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $17 915 228 | 1 128 163 | 0,14% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17 890 408 | 1 126 600 | 0,14% | Opcja kupna |
| HIGHLAND PEAK CAPITAL, LLC | $17 495 488 | 1 101 731 | 0,14% | Akcje |
| THOMPSON INVESTMENT MANAGEMENT, INC. | $17 330 906 | 1 091 367 | 0,14% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $16 660 991 | 1 233 234 | 0,13% | Akcje |
| Bastion Asset Management Inc. | $16 191 713 | 1 052 647 | 0,13% | Akcje |
| QSM Asset Management Ltd | $15 898 267 | 996 132 | 0,13% | Akcje |
| TD Asset Management Inc | $15 844 127 | 997 741 | 0,13% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $15 495 783 | 975 805 | 0,12% | Akcje |
| Sio Capital Management, LLC | $15 154 268 | 954 299 | 0,12% | Akcje |
| PRUDENTIAL FINANCIAL INC | $13 466 796 | 848 035 | 0,11% | Akcje |
| Illinois Municipal Retirement Fund | $13 448 693 | 846 895 | 0,11% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $13 398 528 | 843 736 | 0,11% | Akcje |
| LEVIN CAPITAL STRATEGIES, L.P. | $13 365 809 | 841 676 | 0,11% | Akcje |
| Woodline Partners LP | $12 753 911 | 803 143 | 0,10% | Akcje |
| HSBC HOLDINGS PLC | $12 656 884 | 797 033 | 0,10% | Akcje |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $12 545 248 | 790 003 | 0,10% | Akcje |
| CONTINENTAL ADVISORS LLC | $12 430 070 | 782 750 | 0,10% | Akcje |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $11 932 326 | 751 406 | 0,09% | Akcje |
| Miller Value Partners, LLC | $11 642 644 | 733 164 | 0,09% | Akcje |
| ALGERT GLOBAL LLC | $11 559 052 | 727 900 | 0,09% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11 509 824 | 724 800 | 0,09% | Opcja sprzedaży |
| VestGen Advisors, LLC | $11 228 726 | 707 099 | 0,09% | Akcje |
| Atom Investors LP | $11 206 246 | 705 683 | 0,09% | Akcje |
| STOREBRAND ASSET MANAGEMENT AS | $10 891 425 | 685 858 | 0,09% | Akcje |
| APG Asset Management N.V. | $10 865 473 | 782 273 | 0,09% | Akcje |
| MARSHALL WACE, LLP | $10 826 793 | 681 788 | 0,09% | Akcje |
| LPL Financial LLC | $10 767 536 | 678 057 | 0,09% | Akcje |
| Poehling Capital Management, INC. | $10 675 322 | 672 250 | 0,08% | Akcje |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $10 620 957 | 668 826 | 0,08% | Akcje |
| CITADEL ADVISORS LLC | $10 496 680 | 661 000 | 0,08% | Opcja kupna |
| Sound Income Strategies, LLC | $10 242 156 | 644 972 | 0,08% | Akcje |
Insiderzy spółki 31 insiderów · 14 dyrektorzy generalni · 20 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Scott Andrew Smith | Chief Executive Officer | 6 marca 2026 A | 1 329 326 | 0 | 0 | $0 |
| Michael Goettler | Chief Executive Officer | 4 marca 2023 M | 321 653 | 0 | 0 | $0 |
| Campbell Paul | Interim Chief Financial Officer, Chief Accounting Officer and Corporate Controller | 25 czerwca 2026 S | 316 212 | 0 | 2 | $-1 093 257 |
| Theodora Mistras | Chief Financial Officer | 6 marca 2026 A | 70 645 | 0 | 0 | $0 |
| Sanjeev Narula | Chief Financial Officer | 4 marca 2023 M | 73 877 | 0 | 0 | $0 |
| Anthony Mauro | President, Developed Markets | 13 marca 2024 S | 243 044 | 0 | 0 | $0 |
| Xiangyang (Sean) Ni | President, Greater China | 4 marca 2024 A | 90 804 | 0 | 0 | $0 |
| Andrew Cuneo | President, JANZ (Japan, Australia and New Zealand) and Emerging Markets | 4 marca 2024 A | 60 055 | 0 | 0 | $0 |
| Menassie Taddese | President, Emerging Markets | 27 maja 2022 S | 0 | 0 | 0 | $0 |
| Andrew Enrietti | Chief Administrative and Transformation Officer | 15 sierpnia 2026 M | 234 444 | 0 | 0 | $0 |
| Corinne Le Goff | Chief Commercial Officer | 15 kwietnia 2026 M | 107 135 | 0 | 1 | $-72 078 |
| Matthew Joseph Maletta | Chief Legal Officer | 6 marca 2026 A | — | 0 | 0 | $0 |
| Brian Roman | Chief Legal Officer | 6 marca 2025 A | 193 916 | 0 | 0 | $0 |
| Robert J Coury | Executive Chairman | 4 marca 2023 M | 1 174 515 | 0 | 0 | $0 |
| Leo Frans Groothuis | Dyrektor | 30 czerwca 2026 A | 63 437 | 0 | 0 | $0 |
| David S Simmons | Dyrektor | 30 czerwca 2026 A | 23 344 | 2 | 0 | $5 202 |
| Richard A Mark | Dyrektor | 6 marca 2026 A | 116 145 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Dyrektor | 6 marca 2026 A | 46 526 | 0 | 0 | $0 |
| Michael Severino | Dyrektor | 6 marca 2026 A | 26 031 | 0 | 0 | $0 |
| Dillon Joellen Lyons | Dyrektor | 6 marca 2026 A | 102 526 | 0 | 0 | $0 |
| Mark W Parrish | Dyrektor | 6 marca 2026 A | 165 230 | 0 | 0 | $0 |
| Elisha W Finney | Dyrektor | 6 marca 2026 A | 62 667 | 0 | 0 | $0 |
| Frank A Damelio | Dyrektor | 6 marca 2026 A | 26 031 | 0 | 0 | $0 |
| Don W Cornwell | Dyrektor | 6 marca 2026 A | 112 044 | 0 | 0 | $0 |
| Melina E Higgins | Dyrektor | 6 marca 2026 A | 146 048 | 0 | 0 | $0 |
| James M Kilts | Dyrektor | 6 marca 2026 A | 161 257 | 0 | 0 | $0 |
| Rajiv Malik | Dyrektor | 6 marca 2025 A | 1 068 262 | 0 | 0 | $0 |
| Harry Korman | Dyrektor | 6 marca 2025 A | 113 937 | 0 | 0 | $0 |
| Mohr Pauline Van Der Meer | Dyrektor | 4 marca 2023 M | 40 245 | 0 | 0 | $0 |
| Ian C Read | Dyrektor | 21 marca 2022 M | 14 497 | 0 | 0 | $0 |
| Neil F Dimick | Dyrektor | 21 marca 2022 M | 75 200 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 159 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| DUSA · Davis Fundamental ETF Trust | 4,97% | 3 855 281 NS | 30 kwietnia 2026 | N-PORT |
| IHE · iShares Trust | 4,18% | 4 159 839 SH | 8 sierpnia 2026 | Dziennie |
| ADPV · Series Portfolios Trust | 4,11% | 471 687 NS | 30 kwietnia 2026 | N-PORT |
| DWLD · Davis Fundamental ETF Trust | 4,01% | 1 522 109 NS | 30 kwietnia 2026 | N-PORT |
| LBAY · Tidal Trust I | 3,80% | 41 162 NS | 31 maja 2026 | N-PORT |
| PJP · Invesco Exchange-Traded Fund Trust | 2,57% | 791 598 SH | 8 sierpnia 2026 | Dziennie |
| LYLD · Cambria ETF Trust | 2,12% | 8 544 NS | 30 kwietnia 2026 | N-PORT |
| SPDV · ETF Series Solutions | 2,08% | 125 516 NS | 30 kwietnia 2026 | N-PORT |
| ABIG · EA Series Trust | 1,97% | 67 399 NS | 29 maja 2026 | N-PORT |
| PTH · Invesco Exchange-Traded Fund Trust | 1,64% | 246 267 SH | 8 sierpnia 2026 | Dziennie |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,58% | 751 666 SH | 8 sierpnia 2026 | Dziennie |
| PILL · Direxion Shares ETF Trust | 1,43% | 12 352 NS | 30 kwietnia 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1,30% | 63 374 SH | 8 sierpnia 2026 | Dziennie |
| RPV · Invesco Exchange-Traded Fund Trust | 1,14% | 1 183 250 SH | 8 sierpnia 2026 | Dziennie |
| SYLD · Cambria ETF Trust | 1,03% | 662 665 NS | 30 kwietnia 2026 | N-PORT |
| BIB · ProShares Trust | 0,94% | 42 565 NS | 31 maja 2026 | N-PORT |
| CZA · Invesco Exchange-Traded Fund Trust | 0,89% | 104 432 SH | 8 sierpnia 2026 | Dziennie |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,71% | 56 727 SH | 8 sierpnia 2026 | Dziennie |
| DFAT · Dimensional ETF Trust | 0,71% | 6 483 864 NS | 30 kwietnia 2026 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0,66% | 251 956 NS | 31 maja 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 0,65% | 7 904 043 NS | 30 kwietnia 2026 | N-PORT |
| QQWZ · Pacer Funds Trust | 0,65% | 20 246 NS | 30 kwietnia 2026 | N-PORT |
| CVY · Invesco Exchange-Traded Fund Trust | 0,64% | 48 660 SH | 8 sierpnia 2026 | Dziennie |
| AUSF · Global X Funds | 0,55% | 287 430 NS | 31 maja 2026 | N-PORT |
| ITAN · EA Series Trust | 0,51% | 27 790 NS | 29 maja 2026 | N-PORT |
| ABCS · EA Series Trust | 0,50% | 3 459 NS | 29 maja 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,44% | 184 557 NS | 30 kwietnia 2026 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0,40% | 117 672 NS | 30 kwietnia 2026 | N-PORT |
| STNC · Hennessy Funds Trust | 0,40% | 24 403 NS | 30 kwietnia 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,39% | 16 955 526 SH | 8 sierpnia 2026 | Dziennie |
| AVLV · AMERICAN CENTURY ETF TRUST | 0,37% | 2 917 765 NS | 31 maja 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,35% | 10 400 000 | 8 sierpnia 2026 | Dziennie |
| SCHM · SCHWAB STRATEGIC TRUST | 0,35% | 3 114 448 NS | 31 maja 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,34% | 466 740 NS | 30 kwietnia 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,33% | 1 672 565 NS | 30 kwietnia 2026 | N-PORT |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,31% | 91 932 NS | 30 kwietnia 2026 | N-PORT |
| IYH · iShares Trust | 0,31% | 697 150 SH | 8 sierpnia 2026 | Dziennie |
| VFVA · VANGUARD WELLINGTON FUND | 0,28% | 150 960 SH | 8 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,28% | 530 957 NS | 30 kwietnia 2026 | N-PORT |
| RXL · ProShares Trust | 0,27% | 12 010 NS | 31 maja 2026 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,27% | 67 551 NS | 31 maja 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,27% | 3 499 976 SH | 8 sierpnia 2026 | Dziennie |
| VFMF · VANGUARD WELLINGTON FUND | 0,26% | 115 598 SH | 8 sierpnia 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,26% | 49 318 NS | 30 kwietnia 2026 | N-PORT |
| ESML · iShares Trust | 0,26% | 454 086 SH | 8 sierpnia 2026 | Dziennie |
| IMCV · iShares Trust | 0,25% | 179 939 SH | 8 sierpnia 2026 | Dziennie |
| SMMD · iShares Trust | 0,25% | 581 770 SH | 8 sierpnia 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,25% | 22 967 NS | 30 kwietnia 2026 | N-PORT |
| IXJ · iShares Trust | 0,24% | 611 025 SH | 8 sierpnia 2026 | Dziennie |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 115 075 NS | 30 kwietnia 2026 | N-PORT |